Galcanezumab

Drug Profile

Galcanezumab

Alternative Names: LY2951742

Latest Information Update: 22 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Eli Lilly
  • Class Analgesics; Antimigraines; Monoclonal antibodies
  • Mechanism of Action Calcitonin gene-related peptide antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cluster headache; Migraine
  • Discontinued Musculoskeletal pain

Most Recent Events

  • 14 Jun 2017 Efficacy data from a phase II trial in Musculoskeletal pain presented at the 18th Annual Congress of the European League Against Rheumatism (EULAR-2017)
  • 10 Jun 2017 Updated efficacy data from three phase III trials, EVOLVE-1, EVOLVE-2 and REGAIN in Migrain released by Eli Lilly
  • 12 May 2017 Eli Lilly announces intention to submit BLA to US-FDA for Migraine (Prevention) in the second half of 2017, followed by submissions to other regulatory agencies around the world.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top